Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,125,561 | 1,671,861 | 1,823,831 | 3,536,007 | 1,718,659 |
| Depreciation Amortization | 3,791,718 | 2,580,715 | 1,300,827 | 5,260,907 | 4,034,698 |
| Accounts receivable | 723,738 | -502,229 | -380,699 | -87,570 | -479,117 |
| Accounts payable and accrued liabilities | -15,814 | -82,291 | -226,171 | 344,228 | -48,787 |
| Other Working Capital | -262,046 | -1,552,151 | -1,712,174 | 2,592,341 | 307,603 |
| Other Operating Activity | 215,028 | 1,524,195 | 712,794 | -2,143,162 | 322,666 |
| Operating Cash Flow | $6,578,185 | $3,640,100 | $1,518,408 | $9,502,751 | $5,855,722 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -767,897 | -547,929 | -270,807 | -608,678 | -309,341 |
| Net Acquisitions | -418,299 | -231,240 | -231,240 | 4,985,647 | 1,199,702 |
| Purchase Of Investment | -66,880 | -32,678 | -29,584 | -118,402 | -90,998 |
| Sale Of Investment | 141,372 | 91,637 | 4,395 | 701,278 | 707,683 |
| Purchase Sale Intangibles | -409,561 | -229,156 | -113,331 | -1,177,463 | -474,902 |
| Other Investing Activity | -406,182 | -220,266 | -113,814 | -1,260,662 | -545,136 |
| Investing Cash Flow | $-1,517,886 | $-940,476 | $-641,050 | $3,699,182 | $961,910 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,194,139 | N/A | N/A | 11,087,440 | 11,323,340 |
| Debt Repayment | -5,588,414 | -4,013,755 | -2,210,563 | -15,526,040 | -13,335,380 |
| Common Stock Repurchased | -462,334 | -23,132 | -23,132 | -20,125 | -20,525 |
| Dividend Paid | -2,402,611 | -1,288,314 | -1,201,491 | -2,663,556 | -2,636,918 |
| Other Financing Activity | -1,013,672 | -666,284 | -305,260 | -3,108,249 | -2,226,024 |
| Financing Cash Flow | $-7,272,892 | $-5,991,485 | $-3,740,446 | $-10,230,530 | $-6,895,507 |
| Exchange Rate Effect | 84,031 | 30,958 | 30,248 | 117,509 | -113,251 |
| Beginning Cash Position | 8,502,754 | 8,792,620 | 8,792,620 | 5,993,572 | 6,121,094 |
| End Cash Position | 6,374,201 | 5,531,717 | 5,959,772 | 9,082,486 | 5,929,968 |
| Net Cash Flow | $-2,128,553 | $-3,260,903 | $-2,832,848 | $3,088,915 | $-191,126 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,578,185 | 3,640,100 | 1,518,408 | 9,502,751 | 5,855,722 |
| Capital Expenditure | -771,522 | -551,469 | -271,526 | -1,045,336 | -720,394 |
| Free Cash Flow | 5,806,663 | 3,088,631 | 1,246,882 | 8,457,415 | 5,135,328 |